ADALAT XL TABLET (EXTENDED-RELEASE)

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

NIFEDIPINE

Saatavilla:

BAYER INC

ATC-koodi:

C08CA05

INN (Kansainvälinen yleisnimi):

NIFEDIPINE

Annos:

30MG

Lääkemuoto:

TABLET (EXTENDED-RELEASE)

Koostumus:

NIFEDIPINE 30MG

Antoreitti:

ORAL

Kpl paketissa:

28/98

Prescription tyyppi:

Prescription

Terapeuttinen alue:

DIHYDROPYRIDINES

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0115253004; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

1995-02-27

Valmisteyhteenveto

_ADALAT XL Product Monograph_
Page 1 of 40
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ADALAT® XL®
Nifedipine extended-release tablets
Tablet, 30 mg, oral
Bayer Standard
Antianginal/Antihypertensive Agent
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Date of Initial Authorization:
March 26, 1992
Date of Revision:
June 29, 2023
Submission Control No: 270254
©
2023, Bayer Inc.
®TM see www.bayer.ca/tm-mc. All other trademarks are the property of
their respective
owners.
_ADALAT XL Product Monograph_
Page 2 of 40
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE
OF
CONTENTS
................................................................................................................2
PART
I:
HEALTH
PROFESSIONAL
INFORMATION
........................................................................3
1
INDICATIONS
.........................................................................................................................3
1.1
PEDIATRICS........................................................................................................................3
1.2 GERIATRICS
........................................................................................................................3
2
CONTRAINDICATIONS............................................................................................................3
4
DOSAGE
AND
ADMINISTRATION............................................................................................4
4.1 DOSING CONSIDERATIONS
....................................................................................................4
4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT
.................................................................4
4.4
ADMINISTRATION................................................................................................................5
4.5 MISSED DOSE
........................................................................